Preclinical research reveals that clozapine disrupts the gut-lung microbiota axis, linking its common side effect of gastrointestinal hypomotility to increased susceptibility to respiratory infections, offering a mechanistic explanation for clozapine-associated pneumonia.

A single dose of psilocybin induces measurable changes in the human brain, providing mechanistic insight into its psychedelic effects relevant to psychiatric treatment research.

Research identifies that lithium modulates specific brain signals associated with suicide risk, providing mechanistic insight into its anti-suicidal effects.

This study demonstrates that individual responsiveness to experimental placebo effects on emotional processing predicts the magnitude of clinical expectation-driven symptom improvement in patients undergoing antidepressant treatment, highlighting expectation sensitivity as a potential target for optimizing depression therapy.

A correction to a network meta-analysis clarifies that while quetiapine remains the preferred second-generation antipsychotic for pregnancy safety, the previously reported increased teratogenic risk for several other antipsychotics and lithium was not statistically significant after removing duplicated data.

Discussion of psilocybin's safety profile and efficacy signals for chronic suicidal ideation, highlighting the role of patient expectations in treatment outcomes.

A clinical trial evaluating a multimodal personalized intervention combining the antidiabetic drug semaglutide with lifestyle and neuromodulation therapies for severe mental illnesses including depression, bipolar disorder, and schizophrenia.

UC Davis researchers developed non-hallucinogenic psychedelic-like compounds targeting serotonin receptors for potential treatment of depression, PTSD, and addiction.

Enveric Biosciences has secured a patent for psilocybin derivatives, marking a development in the intellectual property landscape for psychedelic therapeutics.

A clinical trial is evaluating psilocybin therapy for mental health issues associated with cancer, representing a psych-indication trial relevant to psychiatric pharmacology.

This Phase 3 trial evaluates the efficacy of semaglutide combined with multimodal lifestyle interventions and transcranial stimulation for severe mental illnesses, offering key insights into the emerging role of metabolic agents and lifestyle psychiatry in treatment-resistant depression, bipolar disorder, and schizophrenia.

A randomized trial published in JAMA Psychiatry indicates that semaglutide improves motivation and reduces effort discounting in patients with major depressive disorder, suggesting a potential off-label therapeutic avenue for anhedonia.

This article features a discussion on the management of rapid cycling bipolar disorder and the role of lithium, providing clinical insights for psychiatrists prescribing mood stabilizers.

An open-label trial evaluates the efficacy and safety of a single dose of psilocybin for treating chronic suicidal ideation, providing early clinical data on this psychedelic intervention for high-risk psychiatric symptoms.

An open-label trial of a single 25-mg dose of psilocybin for chronic suicidal ideation in patients with treatment-resistant depression provides early efficacy and safety data for this high-risk population.

A decade-long claims data analysis reveals that clozapine prescribing in Germany has significantly decreased despite guideline updates, highlighting persistent underutilization and substantial regional disparities in treatment for treatment-resistant schizophrenia.

This letter critiques a systematic review and network meta-analysis regarding the comparative safety of antipsychotics and mood stabilizers during pregnancy, highlighting methodological concerns relevant to prescribing in this population.

This article is an author's reply to a comment on a systematic review and network meta-analysis evaluating the comparative safety of antipsychotics and mood stabilizers during pregnancy regarding congenital malformations.

A post hoc analysis of clinical trials for once-monthly aripiprazole calculates NNT, NNH, and LHH metrics to quantify the benefit-risk profile for schizophrenia treatment.

This review of immunomodulatory drug trials in psychiatry highlights mixed efficacy results and emphasizes the need for biomarker-driven patient selection and long-term monitoring to advance precision medicine in psychiatric pharmacotherapy.

This study identifies high resting motor threshold and low prefrontal cortical activation as distinct neurophysiological markers in adolescent depression, suggesting the need for developmentally tailored rTMS dosing and targeting strategies.

Genetic research identifies distinct and shared molecular pathways linking cannabis use disorder and psychosis, potentially aiding in risk identification and targeted interventions.

A study from Children’s Hospital Los Angeles investigates the utility of genetic testing to guide SSRI prescribing in pediatric patients, highlighting ongoing research into pharmacogenomics for antidepressant efficacy.

Cost-effectiveness analysis establishes value-based pricing thresholds for Alzheimer's disease disease-modifying therapies (lecanemab and donanemab) across 174 countries, informing global reimbursement strategies.

An executive order accelerating psychedelics research coincides with legislative or regulatory developments regarding psilocybin in New York, highlighting the evolving landscape of psychedelic-assisted therapy.

Robert F. Kennedy Jr. has expressed goals to reduce the overuse of antidepressant drugs in the United States, highlighting a policy and regulatory perspective on psychopharmacology prescribing practices.

A consensus of 42 experts has established best practices for initiating medications for opioid use disorder (MOUD) within hospital settings.

Psilocybin is emerging as a potential therapeutic agent for smoking cessation, indicating a new application for this psychedelic compound in substance use disorder treatment.